SRIF-14
SRIF-14
SRIF-14, also known as Somatostatin-14, is a peptide hormone that plays a crucial role in the human endocrine system. It is a shorter form of somatostatin, a hormone that inhibits the secretion of several other hormones. This article provides a comprehensive overview of SRIF-14, its structure, function, and clinical significance.
Structure[edit | edit source]
SRIF-14 is a cyclic peptide composed of 14 amino acids. Its sequence is as follows: Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys. The peptide forms a disulfide bond between the two cysteine residues, creating a cyclic structure that is essential for its biological activity.
Function[edit | edit source]
SRIF-14 functions primarily as an inhibitory hormone. It is produced by the delta cells of the pancreas, the hypothalamus, and the gastrointestinal tract. Its main actions include:
- Inhibition of growth hormone secretion from the anterior pituitary gland.
- Suppression of insulin and glucagon secretion from the pancreas.
- Reduction of gastric acid secretion and gastrointestinal motility.
SRIF-14 exerts its effects by binding to specific somatostatin receptors, which are G-protein-coupled receptors located on the surface of target cells. There are five known subtypes of somatostatin receptors (SSTR1-5), and SRIF-14 can bind to all of them, although with varying affinities.
Clinical Significance[edit | edit source]
SRIF-14 has several clinical applications due to its inhibitory effects on hormone secretion. It is used in the treatment of conditions such as:
- Acromegaly: A disorder characterized by excessive growth hormone production. SRIF-14 analogs can help reduce growth hormone levels.
- Neuroendocrine tumors: These tumors often secrete hormones that can cause symptoms. SRIF-14 analogs can help control hormone secretion and alleviate symptoms.
- Gastrointestinal bleeding: SRIF-14 can reduce blood flow to the gastrointestinal tract and decrease bleeding.
Research and Development[edit | edit source]
Research on SRIF-14 and its analogs continues to expand, with ongoing studies exploring their potential in treating various endocrine and non-endocrine disorders. Advances in peptide synthesis and receptor targeting are enhancing the therapeutic potential of SRIF-14 analogs.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
